ClinicalTrials.gg
Not yet recruitingNCT07946380MESO-PDACUpdated Nov 18, 2026

Mesopancreas Excision in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma

An interventional study of Pancreaticoduodenectomy with total mesopancreas excision and Standard pancreaticoduodenectomy in Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms and Pancreatic Head Cancer, sponsored by Minia University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Minia University · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies in Pancreatic Neoplasms by Minia University — 11 open to participants now, 11 under way, 1 of them phase 3. Pancreatic Neoplasms · Minia University.

Planned enrollment
3rd of 10
110 · median 100
Started
2026
with 1 other
No phase
6 of 13
6 open now
Primary completion
2027-12
later than 6 of 10 live
Registered
12th of 13
by date

Among the 13 studies in Pancreatic Neoplasms by Minia University, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 12th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

11 of the 13 studies in Pancreatic Neoplasms by Minia University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pancreatic Neoplasms by Minia University, or all of them as a file.
02

Study summary

Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is treated when it arises in the head of the pancreas and can be removed by an operation called pancreaticoduodenectomy (the Whipple operation), followed by chemotherapy. Even after this operation the cancer returns in most patients. One important reason is that microscopic cancer cells are often left at the cut edges of the removed tissue, especially at the edge facing the superior mesenteric artery, the main artery that supplies the intestine. The tissue in this area, behind the head of the pancreas, is called the mesopancreas. It contains fat, lymph vessels, lymph nodes and nerves, through which pancreatic cancer commonly spreads.

Total mesopancreas excision is a refinement of the standard operation. The surgeon removes the whole mesopancreas in one piece together with the head of the pancreas by dissecting directly along the right side of the superior mesenteric artery, in the same way that the whole fatty envelope of the rectum is removed in rectal cancer surgery. Studies that compared patients operated on with and without this technique suggest that it may leave fewer cancer cells behind and reduce the chance of the cancer returning in the operated area, without increasing complications. Those studies were not randomized, however, so it is still unknown whether the technique itself is responsible for these benefits.

In this single-center randomized controlled trial, 110 adults with removable (resectable) cancer of the head of the pancreas will be assigned by chance, during the operation and after the surgeon has confirmed that the tumor can be removed, to pancreaticoduodenectomy with total mesopancreas excision or to standard pancreaticoduodenectomy. Patients, and the doctors who examine the removed tissue and the follow-up scans, will not be told which operation was performed. The main question is whether total mesopancreas excision increases the proportion of patients in whom no cancer cells are found within 1 mm of any cut edge (an R0 resection). The trial will also compare complications, diarrhea, recovery, the number of lymph nodes removed, the chance and pattern of cancer recurrence, survival and quality of life over 2 years of follow-up.

Read the detailed description

BACKGROUND AND RATIONALE

Pancreaticoduodenectomy followed by adjuvant chemotherapy is the standard treatment for resectable pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head, but most patients develop recurrence, often within 2 years (Groot et al., 2018). Microscopic involvement of the resection margins is a major cause of locoregional failure. When pancreaticoduodenectomy specimens are examined with a standardized protocol of multicolor inking and axial slicing and the 1-mm rule is applied, most PDAC resections are classified as R1 (Verbeke et al., 2006; Esposito et al., 2008; Campbell et al., 2009), and the mesopancreatic margin facing the superior mesenteric artery (SMA) is the most frequently involved site (Gaedcke et al., 2010).

The mesopancreas, introduced as a surgical concept by Gockel et al. (2007), is the retropancreatic compartment of adipose, lymphatic and neural tissue that extends from the pancreatic head and uncinate process to the SMA and the aorta. Total mesopancreas excision (TMpE), analogous to total mesorectal excision for rectal cancer, removes this compartment en bloc by a periadventitial dissection along the right side of the SMA (Adham and Singhirunnusorn, 2012; Kawabata et al., 2012; Inoue et al., 2015). Comparative series have reported higher R0 rates (Kawabata et al., 2012; Xu et al., 2017; Shyr et al., 2025) and larger lymph node yields with fewer locoregional recurrences (Xu et al., 2017; Quero et al., 2020) after TMpE than after standard pancreaticoduodenectomy. A 2024 meta-analysis of nine non-randomized studies (738 patients) found a higher R0 rate (risk ratio 1.24), fewer local recurrences (risk ratio 0.39) and no increase in overall morbidity or mortality, with a non-significant increase in postoperative diarrhea (da Silva et al., 2024). The 2026 international MESODELPHI consensus agreed on a unified definition and boundaries of the mesopancreas, favored TMpE for curative-intent surgery, and called for further investigation of its effect on survival (Leite et al., 2026). No randomized trial comparing TMpE with standard pancreaticoduodenectomy has been published (Ramia et al., 2018; da Silva et al., 2024).

At the Liver and GIT Hospital, Minia University, a single-arm cohort of 86 patients who underwent pancreaticoduodenectomy with mesopancreas excision for PDAC between 2018 and 2024 had an R0 rate of 84.9% under the Royal College of Pathologists 1-mm rule; recurrence developed in 52 patients (60.5%), with a locoregional component in 31 of them (Saleh et al., 2026). Because that study, like most of the literature, had no control group, the oncological benefit of TMpE over standard pancreaticoduodenectomy remains unproven and requires a randomized comparison.

OBJECTIVES AND HYPOTHESIS

The primary objective is to determine whether pancreaticoduodenectomy with TMpE increases the R0 resection rate, defined as tumor clearance of 1 mm or more at all resection margins, compared with standard pancreaticoduodenectomy in patients with resectable PDAC of the pancreatic head. The hypothesis is that TMpE increases the R0 rate from 60% to 85%.

The secondary objectives are to compare SMA-margin involvement, lymph node yield, locoregional and distant recurrence, disease-free and overall survival, postoperative morbidity (including pancreatic fistula, hemorrhage, delayed gastric emptying, chyle leak and diarrhea), recovery, delivery of adjuvant chemotherapy and quality of life between the two operations.

STUDY DESIGN AND SETTING

This is a single-center, randomized, parallel-group (1:1) superiority trial with masked participants and masked outcome assessors, conducted at the Department of Surgery, Liver and GIT Hospital, Faculty of Medicine, Minia University, Minya, Egypt. The protocol follows the SPIRIT 2025 statement, and the trial will be reported according to CONSORT 2025 and its extension for non-pharmacologic treatments.

SCREENING AND STAGING

Consecutive adults referred with a mass in the pancreatic head or uncinate process are screened. Staging consists of pancreatic-protocol contrast-enhanced multidetector CT of the chest, abdomen and pelvis within 4 weeks before surgery, serum CA19-9, and endoscopic ultrasound with fine-needle aspiration or biopsy when the multidisciplinary tumor board requires a tissue diagnosis. Resectability is defined by NCCN criteria (Tempero et al., 2021). Preoperative biliary drainage is reserved for cholangitis, severe jaundice or an expected delay to surgery, according to unit policy.

RANDOMIZATION AND ALLOCATION CONCEALMENT

A statistician not involved in recruitment or treatment generates the allocation sequence by computer, using permuted blocks of variable size (4 and 6) stratified by venous contact on preoperative CT (no contact versus contact of 180 degrees or less with the superior mesenteric vein or portal vein). Allocations are kept in sequentially numbered, opaque, sealed envelopes outside the operating room. Written informed consent is obtained before surgery. Randomization takes place during the operation, after exploration has excluded peritoneal and liver metastases and confirmed local resectability, when the circulating nurse opens the next envelope of the relevant stratum. Patients found to be unresectable before randomization are not randomized and are recorded as screening failures.

MASKING

The operating surgeons cannot be masked. Participants are not told their allocation until follow-up is complete. Specimens are sent to pathology labeled with the trial number only, with a request form that does not state the allocation, and a second pathologist re-measures the margin distances on the slides. Postoperative complications are graded, and follow-up imaging is reviewed for recurrence, by investigators who did not take part in the operation and are masked to allocation. The statistician analyzes a dataset in which the arms are coded.

INTERVENTIONS

Both arms: All operations are open pancreaticoduodenectomies, pylorus-preserving or pylorus-resecting according to tumor extent, performed by senior hepatopancreatobiliary surgeons of the unit who have used TMpE since 2018 and perform more than 50 pancreaticoduodenectomies per year. Both arms receive the ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b; Tol et al., 2014). Portal or superior mesenteric vein resection is performed in either arm when needed for tumor clearance. Reconstruction, drain policy, antibiotic and thromboembolic prophylaxis, and the enhanced-recovery pathway are the same in both arms.

Experimental arm (TMpE): An artery-first approach exposes the SMA at its origin to confirm the absence of arterial involvement. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the SMA anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and SMA superiorly; and the lower border of the uncinate process and the first jejunal vessels inferiorly. The SMA is dissected in the periadventitial plane over its right hemicircumference (about 180 degrees) from the aortic origin to the origin of the first jejunal artery. The inferior pancreaticoduodenal artery, or its common trunk with the first jejunal artery, is ligated at its origin, and the right-sided SMA nerve plexus is removed with the specimen while the left-sided plexus is preserved. Extension of the periarterial clearance up to 270 degrees is allowed only when periarterial tumor extension is suspected during surgery and is recorded as a protocol variation.

Control arm (standard pancreaticoduodenectomy): A conventional vein-first approach is used (Kocher maneuver, tunneling behind the pancreatic neck and transection of the neck). The uncinate process is divided from the superior mesenteric vein and from the right side of the SMA, ligating the pancreaticoduodenal branches close to the pancreas. The SMA is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment; station 14a and 14b nodes are removed superficial to the nerve plexus.

Surgical quality assurance: Standardized photographs of the operative field after resection and of the specimen are taken in every case and reviewed by an independent senior surgeon to confirm that the allocated technique was performed. Crossovers and protocol deviations are documented.

PATHOLOGY PROTOCOL

The surgeon marks the SMA margin and the superior mesenteric vein groove with sutures. Specimens are examined with a standardized protocol based on multicolor inking of the margins and surfaces, axial slicing perpendicular to the duodenal axis at 3 to 5 mm intervals, and extensive sampling (Verbeke et al., 2006). The minimum distance between tumor and each margin is measured microscopically. R0 is defined as clearance of 1 mm or more at all resection margins (SMA, superior mesenteric vein/portal vein groove, posterior, pancreatic neck, bile duct, and proximal and distal enteric margins). R1 is defined as tumor less than 1 mm from any resection margin and is subdivided into direct (0 mm) and indirect (more than 0 mm and less than 1 mm) involvement. Involvement of the anterior pancreatic surface is recorded separately. Lymph nodes are reported by station, staging follows the 8th edition of the AJCC/UICC TNM classification, and perineural, lymphovascular and retropancreatic soft-tissue invasion are recorded.

POSTOPERATIVE CARE, ADJUVANT THERAPY AND FOLLOW-UP

Complications are recorded prospectively for 90 days and graded by the Clavien-Dindo classification (Dindo et al., 2004) and the Comprehensive Complication Index (Slankamenac et al., 2013). Postoperative pancreatic fistula, delayed gastric emptying, post-pancreatectomy hemorrhage and chyle leak follow the ISGPS definitions (Bassi et al., 2017; Wente et al., 2007a; Wente et al., 2007b; Besselink et al., 2017). Diarrhea is graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at every visit for 6 months. Adjuvant chemotherapy is decided by the clinical oncology team, which is masked to allocation: modified FOLFIRINOX for fit patients or gemcitabine plus capecitabine, planned for 6 months and started within 12 weeks of surgery (Neoptolemos et al., 2017; Conroy et al., 2018). Follow-up visits occur at 1, 3, 6, 9, 12, 18 and 24 months, with clinical examination and serum CA19-9 at each visit. Contrast-enhanced CT of the chest, abdomen and pelvis is performed at 3, 6, 9, 12, 18 and 24 months and whenever recurrence is suspected, with MRI, PET-CT or biopsy when needed. Recurrence is classified as locoregional (pancreatic or mesopancreatic bed around the SMA, celiac axis and superior mesenteric vein/portal vein, anastomoses, or regional lymph nodes), distant (liver, lungs, peritoneum, bone, non-regional lymph nodes or other organs) or combined, and is adjudicated by a radiologist masked to allocation. Quality of life is assessed with the EORTC QLQ-C30 at baseline and at 3, 6 and 12 months.

SAMPLE SIZE

The sample size is based on the primary outcome. The expected R0 rate is 60% after standard pancreaticoduodenectomy (Kawabata et al., 2012) and 85% after TMpE, based on the institutional series in which a comparable protocol (axial slicing, margin inking and the 1-mm rule) gave an R0 rate of 84.9% (Saleh et al., 2026). A difference of this size is consistent with the higher R0 rates reported in comparative series and with the mesopancreatic margin being the most common site of R1 resection (Gaedcke et al., 2010; da Silva et al., 2024). Detecting it with 80% power and a two-sided alpha of 0.05 (chi-square test) requires 49 participants per arm. Allowing 10% for post-randomization exclusions (final histology other than PDAC, or withdrawal), 55 participants per arm will be randomized (110 in total). Recruitment is planned over 12 months, from December 2026 to November 2027.

STATISTICAL ANALYSIS

The primary analysis follows a modified intention-to-treat approach: all randomized participants with histologically confirmed PDAC, analyzed in the arm to which they were allocated. A per-protocol analysis excluding crossovers and major protocol deviations is a sensitivity analysis. R0 rates are compared with the chi-square test and reported as the absolute risk difference and risk ratio with 95% confidence intervals; logistic regression adjusted for the stratification factor is a supportive analysis. Other categorical outcomes are compared with the chi-square or Fisher exact test, and continuous outcomes with the t-test or Mann-Whitney U test. Disease-free and overall survival are estimated by the Kaplan-Meier method, compared with the log-rank test and modeled with Cox regression adjusted for the stratification factor. Locoregional and distant recurrence are analyzed as cumulative incidence with death as a competing event (Gray test and Fine-Gray model). Quality-of-life scores are analyzed with linear mixed models. Prespecified subgroup analyses of the primary outcome are by venous contact and by tumor size on CT (2 cm or less versus more than 2 cm). Missing secondary outcome data are handled by multiple imputation if more than 5% are missing. All tests are two-sided at a significance level of 0.05; secondary outcomes are not adjusted for multiplicity and are interpreted as exploratory. Analyses are performed with SPSS version 26 and R.

DATA MANAGEMENT AND MONITORING

Data are recorded on standardized case report forms and entered into a password-protected database with coded identifiers; the primary outcome is verified against source documents for every participant. An independent data and safety monitoring board (a hepatopancreatobiliary surgeon, a clinical oncologist and a biostatistician, none involved in the trial) reviews unmasked safety data, including 90-day mortality, complications of Clavien-Dindo grade IIIa or higher, grade B or C pancreatic fistula and hemorrhage, and diarrhea of CTCAE grade 3 or higher, after 30 and after 55 participants have completed 90 days of follow-up, and may recommend modification or early termination for safety. No interim efficacy analysis is planned. Serious adverse events are reported to the Institutional Review Board according to its requirements.

ETHICS AND DISSEMINATION

The protocol was approved by the Institutional Review Board, Faculty of Medicine, Minia University (MUFMIRB approval number 1702:09/2025, 15 September 2025). The trial is conducted in accordance with the Declaration of Helsinki, ICH Good Clinical Practice and Egyptian Law No. 214 of 2020 on clinical medical research. All participants give written informed consent before surgery, including consent to randomization during the operation, and may withdraw at any time without any effect on their care. Results will be published in a peer-reviewed journal and reported on ClinicalTrials.gov regardless of the findings.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Neoplasms
  • Pancreatic Head Cancer

Keywords

  • Total mesopancreas excision
  • Mesopancreas
  • Pancreaticoduodenectomy
  • Whipple procedure
  • R0 resection
  • Resection margin
  • Superior mesenteric artery
  • Artery-first approach
  • Lymphadenectomy
  • Local recurrence
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years.
  • Solid tumor of the pancreatic head or uncinate process with a cytological or histological diagnosis of pancreatic ductal adenocarcinoma or, when a tissue diagnosis is not available, imaging features typical of pancreatic ductal adenocarcinoma accepted by the multidisciplinary tumor board.
  • Resectable disease according to NCCN criteria on pancreatic-protocol contrast-enhanced CT performed within 4 weeks before surgery: no arterial tumor contact (celiac axis, superior mesenteric artery or common hepatic artery), and no contact with the superior mesenteric vein or portal vein or contact of 180 degrees or less without vein contour irregularity.
  • Planned upfront open pancreaticoduodenectomy with curative intent.
  • performance status 0 or 1.
  • (ASA) physical status I to III.
  • Written , including consent to randomization during surgery.
  • Confirmation at laparotomy, before randomization, of no peritoneal or liver and no tumor involvement of the superior mesenteric artery, celiac axis or common hepatic artery.

Exclusion criteria

Exclusion Criteria:

  • Borderline resectable or locally advanced disease, or distant , on preoperative staging.
  • Previous chemotherapy, chemoradiotherapy or radiotherapy for the current tumor.
  • Preoperative diagnosis of another tumor type, including ampullary, distal bile duct or duodenal carcinoma, neuroendocrine neoplasm, acinar cell carcinoma, solid pseudopapillary neoplasm or lymphoma.
  • Planned total pancreatectomy or arterial resection.
  • Planned laparoscopic or robotic pancreaticoduodenectomy.
  • Previous pancreatic resection, or previous major surgery around the superior mesenteric vessels or in the retroperitoneum near the pancreas.
  • Liver cirrhosis of class B or C, or portal hypertension.
  • Other active , or previous malignancy within 5 years other than non-melanoma skin cancer or carcinoma in situ of the cervix.
  • Emergency surgery for bleeding or perforation.
  • Pregnancy or breastfeeding.
  • Inability to attend follow-up or to give .
  • Participation in another interventional trial that could affect the study outcomes.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Pancreaticoduodenectomy With Total Mesopancreas Excision

    Open pancreaticoduodenectomy using an artery-first approach with en bloc total mesopancreas excision: periadventitial dissection of the right hemicircumference (about 180 degrees) of the superior mesenteric artery from its aortic origin to the first jejunal artery, ligation of the inferior pancreaticoduodenal artery at its origin, and removal of the retropancreatic fat, lymphatic and neural tissue (including the right-sided superior mesenteric artery nerve plexus) down to the inferior vena cava, left renal vein and aorta, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the control arm.

    Procedure: Pancreaticoduodenectomy with total mesopancreas excision

  • Active comparator
    Standard Pancreaticoduodenectomy

    Open pancreaticoduodenectomy using the conventional vein-first approach, with division of the uncinate process from the superior mesenteric vein and the right side of the superior mesenteric artery close to the pancreas, without periadventitial dissection of the artery or resection of its nerve plexus, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the experimental arm.

    Procedure: Standard pancreaticoduodenectomy

Interventions

  • ProcedurePancreaticoduodenectomy with total mesopancreas excision

    Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) with an artery-first approach. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the superior mesenteric artery anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and superior mesenteric artery superiorly; and the lower border of the uncinate process inferiorly. The artery is cleared in the periadventitial plane over about 180 degrees on its right side from the aorta to the first jejunal artery, with ligation of the inferior pancreaticoduodenal artery at its origin; the left-sided nerve plexus is preserved. Extension up to 270 degrees is allowed only for suspected periarterial tumor extension. ISGPS standard lymphadenectomy.

    Also known as: Total mesopancreas excision (TMpE), Mesopancreas excision, Systematic mesopancreas dissection

  • ProcedureStandard pancreaticoduodenectomy

    Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) using the conventional vein-first approach: Kocher maneuver, tunneling behind the pancreatic neck and neck transection, then division of the uncinate process from the superior mesenteric vein and from the right side of the superior mesenteric artery, with ligation of the pancreaticoduodenal branches close to the pancreas. The artery is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment. ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b), with station 14a and 14b nodes removed superficial to the nerve plexus.

    Also known as: Whipple procedure, Conventional pancreaticoduodenectomy

06

What researchers measure

Primary outcomes

  1. R0 Resection Rate (Tumor Clearance of 1 mm or More at All Resection Margins)

    Proportion of participants with an R0 resection on final histopathology. R0 is defined as a minimum microscopic distance of 1 mm or more between tumor and every resection margin (superior mesenteric artery margin, superior mesenteric vein/portal vein groove margin, posterior margin, pancreatic neck transection margin, bile duct margin, and proximal and distal enteric margins), assessed with a standardized protocol of multicolor inking and axial slicing. Pathologists are masked to allocation, and a second pathologist re-measures margin distances on the slides. Analyzed in randomized participants with histologically confirmed pancreatic ductal adenocarcinoma.

    Time frame: Final histopathology report, within 3 weeks after surgery

Secondary outcomes

  1. Superior Mesenteric Artery (Mesopancreatic) Margin Involvement

    Proportion of participants with tumor less than 1 mm from the inked superior mesenteric artery (mesopancreatic) margin on final histopathology.

    Time frame: Final histopathology report, within 3 weeks after surgery

  2. R1 Direct Resection Rate (Tumor at a Resection Margin)

    Proportion of participants with tumor cells at the inked surface (0 mm) of any resection margin on final histopathology.

    Time frame: Final histopathology report, within 3 weeks after surgery

  3. Number of Lymph Nodes Examined

    Total number of lymph nodes retrieved from the resection specimen and examined histologically.

    Time frame: Final histopathology report, within 3 weeks after surgery

  4. Locoregional Recurrence

    Cumulative incidence of locoregional recurrence (pancreatic or mesopancreatic bed around the superior mesenteric artery, celiac axis and superior mesenteric vein/portal vein, surgical anastomoses, or regional lymph nodes), isolated or combined with distant recurrence, diagnosed on contrast-enhanced CT with MRI, PET-CT or biopsy when required and adjudicated by a radiologist masked to allocation. Death without recurrence is treated as a competing event.

    Time frame: From surgery up to 24 months

  5. Distant Recurrence

    Cumulative incidence of recurrence in the liver, lungs, peritoneum, bone, non-regional lymph nodes or other distant sites, diagnosed and adjudicated as for locoregional recurrence. Death without recurrence is treated as a competing event.

    Time frame: From surgery up to 24 months

  6. Disease-Free Survival

    Time from surgery to first recurrence at any site or death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year disease-free survival rate.

    Time frame: From surgery up to 24 months

  7. Overall Survival

    Time from surgery to death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year overall survival rate.

    Time frame: From surgery up to 24 months

  8. Operative Time

    Time from skin incision to completion of skin closure, in minutes.

    Time frame: During surgery

  9. Intraoperative Blood Loss

    Estimated blood loss in milliliters, measured from suction volume and weighed swabs.

    Time frame: During surgery

  10. Overall Postoperative Morbidity

    Proportion of participants with at least one postoperative complication of any grade according to the Clavien-Dindo classification.

    Time frame: Within 90 days after surgery

  11. Major Postoperative Morbidity (Clavien-Dindo Grade IIIa or Higher)

    Proportion of participants with at least one complication of Clavien-Dindo grade IIIa or higher.

    Time frame: Within 90 days after surgery

  12. Comprehensive Complication Index

    Cumulative burden of all postoperative complications on a continuous scale from 0 (no complication) to 100 (death).

    Time frame: Within 90 days after surgery

  13. Clinically Relevant Postoperative Pancreatic Fistula (ISGPS Grade B or C)

    Proportion of participants with grade B or C postoperative pancreatic fistula according to the 2016 International Study Group of Pancreatic Surgery (ISGPS) definition.

    Time frame: Within 90 days after surgery

  14. Post-Pancreatectomy Hemorrhage (ISGPS Grade B or C)

    Proportion of participants with grade B or C post-pancreatectomy hemorrhage according to the ISGPS definition.

    Time frame: Within 90 days after surgery

  15. Delayed Gastric Emptying (ISGPS Grade B or C)

    Proportion of participants with grade B or C delayed gastric emptying according to the ISGPS definition.

    Time frame: Within 90 days after surgery

  16. Chyle Leak (ISGPS Grade B or C)

    Proportion of participants with grade B or C chyle leak according to the ISGPS definition.

    Time frame: Within 90 days after surgery

  17. Clinically Significant Postoperative Diarrhea (CTCAE Grade 2 or Higher)

    Proportion of participants with diarrhea of grade 2 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, assessed at every visit.

    Time frame: Within 6 months after surgery

  18. Unplanned Reoperation

    Proportion of participants who require an unplanned return to the operating room.

    Time frame: Within 90 days after surgery

  19. Length of Postoperative Hospital Stay

    Number of days from surgery to hospital discharge.

    Time frame: From surgery to discharge, up to 90 days

  20. Hospital Readmission

    Proportion of participants readmitted to hospital after discharge.

    Time frame: Within 90 days after surgery

  21. 90-Day Mortality

    Proportion of participants who die from any cause within 90 days after surgery.

    Time frame: Within 90 days after surgery

  22. Initiation of Adjuvant Chemotherapy Within 12 Weeks

    Proportion of participants who start adjuvant chemotherapy within 12 weeks after surgery.

    Time frame: Within 12 weeks after surgery

  23. Health-Related Quality of Life (EORTC QLQ-C30 Global Health Status)

    Global health status/quality of life score of the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire, from 0 to 100; higher scores indicate better quality of life.

    Time frame: Baseline and 3, 6 and 12 months after surgery

Other outcomes

  1. Minimum Tumor Clearance at the Superior Mesenteric Artery Margin

    Microscopic distance, in millimeters, between the tumor and the inked superior mesenteric artery margin.

    Time frame: Final histopathology report, within 3 weeks after surgery

  2. Lymph Node Ratio

    Number of metastatic lymph nodes divided by the number of lymph nodes examined.

    Time frame: Final histopathology report, within 3 weeks after surgery

  3. Metastasis in Lymph Nodes Along the Superior Mesenteric Artery (Station 14)

    Proportion of participants with at least one metastatic station 14 lymph node.

    Time frame: Final histopathology report, within 3 weeks after surgery

  4. Tumor Invasion of the Retropancreatic Soft Tissue or Nerve Plexus

    Proportion of participants with histological tumor invasion (direct, perineural or lymphovascular) of the resected retropancreatic soft tissue or nerve plexus.

    Time frame: Final histopathology report, within 3 weeks after surgery

  5. Anterior Pancreatic Surface Involvement

    Proportion of participants with tumor at the inked anterior surface of the pancreas (0 mm).

    Time frame: Final histopathology report, within 3 weeks after surgery

  6. Pattern of First Recurrence

    Distribution of first recurrence as isolated locoregional, isolated distant, or combined locoregional and distant recurrence.

    Time frame: From surgery up to 24 months

07

Study locations

1 site
08

References and documents

Publications

  • Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018 May;267(5):936-945. doi: 10.1097/SLA.0000000000002234. PubMed 28338509 ↗
  • Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006 Oct;93(10):1232-7. doi: 10.1002/bjs.5397. PubMed 16804874 ↗
  • Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008 Jun;15(6):1651-60. doi: 10.1245/s10434-008-9839-8. Epub 2008 Mar 20. PubMed 18351300 ↗
  • Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, Ghaneh P. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009 Sep;55(3):277-83. doi: 10.1111/j.1365-2559.2009.03376.x. PubMed 19723142 ↗
  • Gaedcke J, Gunawan B, Grade M, Szoke R, Liersch T, Becker H, Ghadimi BM. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg. 2010 Apr;395(4):451-8. doi: 10.1007/s00423-009-0494-8. Epub 2009 May 6. PubMed 19418067 ↗
  • Gockel I, Domeyer M, Wolloscheck T, Konerding MA, Junginger T. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space. World J Surg Oncol. 2007 Apr 25;5:44. doi: 10.1186/1477-7819-5-44. PubMed 17459163 ↗
  • Adham M, Singhirunnusorn J. Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors. Eur J Surg Oncol. 2012 Apr;38(4):340-5. doi: 10.1016/j.ejso.2011.12.015. Epub 2012 Jan 20. PubMed 22264964 ↗
  • Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol. 2012 Jul;38(7):574-9. doi: 10.1016/j.ejso.2012.04.007. Epub 2012 May 9. PubMed 22575529 ↗
  • Inoue Y, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J, Takahashi Y, Koga R. Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach. Ann Surg. 2015 Dec;262(6):1092-101. doi: 10.1097/SLA.0000000000001065. PubMed 25587814 ↗
  • Xu J, Tian X, Chen Y, Ma Y, Liu C, Tian L, Wang J, Dong J, Cui D, Wang Y, Zhang W, Yang Y. Total mesopancreas excision for the treatment of pancreatic head cancer. J Cancer. 2017 Sep 30;8(17):3575-3584. doi: 10.7150/jca.21341. eCollection 2017. PubMed 29151943 ↗
  • Quero G, Fiorillo C, Menghi R, Cina C, Galiandro F, Longo F, Sofo F, Rosa F, Tortorelli AP, Giustiniani MC, Inzani F, Alfieri S. Total mesopancreas excision for periampullary malignancy: a single-center propensity score-matched comparison of long-term outcomes. Langenbecks Arch Surg. 2020 May;405(3):303-312. doi: 10.1007/s00423-020-01873-4. Epub 2020 Apr 24. PubMed 32333095 ↗
  • Shyr BS, Wang SE, Chen SC, Shyr YM, Shyr BU. Mesopancreas dissection level 3 for pancreatic head cancer in combined robotic/open pancreatoduodenectomy: a propensity score-matched study. Surg Endosc. 2025 Feb;39(2):1191-1199. doi: 10.1007/s00464-024-11475-6. Epub 2024 Dec 29. PubMed 39739104 ↗
  • da Silva LFL, Belotto M, de Almeida LFC, Samuel J, Pereira LH, Albagli RO, de Araujo MS, Ramia JM. Radicality and safety of total mesopancreatic excision in pancreatoduodenectomy: a systematic review and meta-analysis. World J Surg Oncol. 2024 Aug 23;22(1):217. doi: 10.1186/s12957-024-03495-2. PubMed 39180093 ↗
  • Leite LF, Belotto M, Sa de Araujo M, Menezes S, de Almeida LF, Hilal MA, Alcazar Lopez CF, Azagra JS, Balakrishnan A, Berrevoet F, Besselink MG, Blanco-Fernandez G, Boggi U, Chapa-Azuela O, Coimbra FJF, Dasari BVM, Dokmak S, Duarte AA, Falconi M, Oliveira AF, Fusai GK, Frigerio I, Gimenez M, Ielpo B, Inoue Y, Jarufe N, Chavarria EJ, Lesurtel M, Malleo G, Marchegiani G, Mazza O, de Oliveira CVC, O'Rourke N, Pandanaboyana S, Rangelova E, Sabater L, Satoi S, Sauvanet A, Serradilla-Martin M, Siriwardena AK, Sparrelid E, Starlinger P, Stattner S, Strobel O, Sturesson C, Villodre C, Werner J, Galvao do Amaral PC, Peixoto RD, Clavien PA, Ramia JM. International consensus on mesopancreas and total mesopancreas excision (MESODELPHI). HPB (Oxford). 2026 Oct;28(10):1311-1317. doi: 10.1016/j.hpb.2026.06.012. Epub 2026 Jun 30. PubMed 42436071 ↗
  • Ramia JM, De-la-Plaza R, Manuel-Vazquez A, Lopez-Marcano A, Morales R. Systematic review of the mesopancreas: concept and clinical implications. Clin Transl Oncol. 2018 Nov;20(11):1385-1391. doi: 10.1007/s12094-018-1869-5. Epub 2018 Apr 19. PubMed 29675778 ↗
  • Saleh SK, Saleh AG, Mohamed TA, Hendy MM, Farahat MS, Boushra ST, Kamil CM, Saleh RK. Mesopancreas excision in pancreatic ductal adenocarcinoma: recurrence patterns - a single-arm descriptive study. World J Surg Oncol. 2026 Jun 22;24(1):265. doi: 10.1186/s12957-026-04459-4. PubMed 42324571 ↗
  • Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017. PubMed 33845462 ↗
  • Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andren-Sandberg A, Asbun HJ, Bockhorn M, Buchler MW, Conlon KC, Fernandez-Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM; International Study Group on Pancreatic Surgery. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014 Sep;156(3):591-600. doi: 10.1016/j.surg.2014.06.016. Epub 2014 Jul 22. PubMed 25061003 ↗
  • Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. PubMed 15273542 ↗
  • Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013 Jul;258(1):1-7. doi: 10.1097/SLA.0b013e318296c732. PubMed 23728278 ↗
  • Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CM, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584-591. doi: 10.1016/j.surg.2016.11.014. Epub 2016 Dec 28. PubMed 28040257 ↗
  • Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo CJ, Buchler MW. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007 Nov;142(5):761-8. doi: 10.1016/j.surg.2007.05.005. PubMed 17981197 ↗
  • Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Yeo CJ, Buchler MW. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007 Jul;142(1):20-5. doi: 10.1016/j.surg.2007.02.001. PubMed 17629996 ↗
  • Besselink MG, van Rijssen LB, Bassi C, Dervenis C, Montorsi M, Adham M, Asbun HJ, Bockhorn M, Strobel O, Buchler MW, Busch OR, Charnley RM, Conlon KC, Fernandez-Cruz L, Fingerhut A, Friess H, Izbicki JR, Lillemoe KD, Neoptolemos JP, Sarr MG, Shrikhande SV, Sitarz R, Vollmer CM, Yeo CJ, Hartwig W, Wolfgang CL, Gouma DJ; International Study Group on Pancreatic Surgery. Definition and classification of chyle leak after pancreatic operation: A consensus statement by the International Study Group on Pancreatic Surgery. Surgery. 2017 Feb;161(2):365-372. doi: 10.1016/j.surg.2016.06.058. Epub 2016 Sep 28. PubMed 27692778 ↗
  • Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Buchler MW; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25. PubMed 28129987 ↗
  • Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. PubMed 30575490 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 403 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 13 months is below that.

Counting every sponsor, half of 430 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946380
Lead sponsor
Minia University
Responsible party
Saleh Khairy Saleh MD (Lecturer of General Surgery, Minia University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Saleh Khairy Saleh, MD
Contact
salehkhairy@mu.edu.eg
+20 120 176 5401
Saleh Khairy Saleh, MD
principal investigator · Minia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion